| Drug Name |
Asenapine maleate |
| Drug ID |
BADD_D00173 |
| Description |
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. |
| Indications and Usage |
Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination. |
| Marketing Status |
Prescription |
| ATC Code |
N05AH05 |
| DrugBank ID |
DB06216
|
| KEGG ID |
D02995
|
| MeSH ID |
C522667
|
| PubChem ID |
163091
|
| TTD Drug ID |
D00JRA
|
| NDC Product Code |
51991-361; 55111-937; 60870-0468; 0456-2407; 51991-358; 69539-058; 69539-060; 62938-0040; 51991-360; 46708-916; 50379-0004; 50379-0009; 16436-0104; 51991-359; 0456-2402; 17337-0309; 59762-2012; 69539-057; 0456-2412; 65015-817; 62938-0017; 53296-0104; 0456-2404; 59762-1091; 62938-0041; 59762-2888; 0456-2410; 69539-059; 62938-0016; 0456-2405; 51991-928; 69539-245; 64330-625 |
| Synonyms |
asenapine | trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole | asenapine maleate | ORG 5222 | ORG-5222 | 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole | Secuado | Saphris |
